A pair of small biopharmaceutical companies that are seeking a cure for severe acute respiratory syndrome saw their shares jump Friday.

GenVec

(GNVC)

shares were up 64% at $2.52 in late trading, after I the company said it is working on developing a vaccine against SARS with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

Meanwhile,

Medarex

( MEDX) was up 10% at $4.30, following an announcement that the company plans to develop a SARS treatment with the Massachusetts Biologic Laboratories of the University of Massachusetts Medical School.